Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...

Thursday, Bayer shared top-line data from a phase 3 trial that tested elinzanetant in women on adjuvant endocrine therapy for ...

Bayer (BAYZF) (BAYRY) says elinzanetant, its experimental therapy for hot flashes, reached the main goals in a late-stage ...

Vasomotor symptoms are a common problem in women with HR-positive breast cancer receiving anti-cancer therapy.

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

I did not finish that yoga class. Instead, I rolled up my mat and fled the studio for the air-conditioned bathroom where I ...

This article reviews the published literature on the use of venlafaxine, fluoxetine, and paroxetine for the treatment of hot flashes.

As Bayer awaits an FDA decision on its non-hormonal treatment for hot flashes caused by menopause, it's unveiling new results ...

(RTTNews) - Bayer Aktiengesellschaft (BAYRY.PK), Thursday announced that Elinzanetant, a non-hormonal drug, has met all primary and second endpoints in the Phase III study OASIS 4, investigating the ...

The menopausal transition is an opportunity for women to cross a psychological threshold into the second half of life, but ...

Trial confirms elinzanetant's efficacy and safety in addressing vasomotor symptoms caused by adjuvant endocrine therapy in ...

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder ...